IBSA in Frankfurt for CPhI 2022, the reference European event for the pharmaceutical sector17 November 2022
Excellence, new ideas, discovery of new trends, technology and sharing. These are some of the words that best describe the atmosphere that was breathed at CPhI Worldwide, the reference event in Europe for companies and professionals in the pharmaceutical sector, held in Frankfurt (Germany) from 1 to 3 November 2022.
IBSA confirmed once again its presence at the event this year, to meet international industry professionals, expand its network and give great visibility to its products and technologies.
“The outcome of our participation in CPhI Worldwide was certainly positive. The exhibition experienced a good recovery, with a high number of visitors and exhibitors, confirming its role as the main in-person event for the pharmaceutical sector at global level. A positive experience also for IBSA, with many meetings with already consolidated partners, but also several first contacts with potential new partners, interested in our products and technologies”, commented Andrea Giori, Head of Research and Development of IBSA Farmaceutici, the Italian subsidiary of the group.
Andrea Taborelli, Business Development & Licensing Manager of IBSA Group, continued: “Our stand received several visits, especially from industry operators from countries such as Japan, China, Korea, Brazil, Mexico. It was the wide range of our technologies and solutions for the pharmaceutical market that attracted the attention of the attendees. In particular, we recorded a strong interest in the orodispersible film (ODF) technology, applied by IBSA both in the field of food supplements and in the formulation of drugs, as in the case of vitamin D3. At the same time, also products in the areas of fertility, endocrinology and osteoarticular enjoyed success”.
The particularity of the CPhI is that it is a transversal event, which attracts buyers and suppliers from all over the world for three days of networking, training and innovation, covering the entire supply chain, from research and production to packaging and finished products. The great participation – the 2021 edition in Milan was attended by 1,169 exhibitors and 23,300 visitors from 136 countries – and the high specialisation of participants mean that this appointment is increasingly becoming a crucial opportunity to generate quality contacts and expand business development opportunities in the near future.
In particular, this year’s edition offered a rich agenda of events and conferences focused on the topics of innovation, not only in terms of products and technologies, but also the use of the digital world and big data, bringing out some interesting trends that increasingly put the patient at the centre, involving them in the decision-making processes for the development of new technologies. Among the new trends, for example, is the use of the metaverse, to be applied in the relationship with patients, allowing them to access healthcare services remotely, as well as the increasingly massive diffusion of applications considered as actual active medical devices (the so-called “medical device software”).
Furthermore, attention was paid to a very hot and heartfelt topic: sustainability. The implications of reshoring pharmaceutical production in Europe – i.e. the reversal of relocations, with the return of part of the production to corporate headquarters – and the need of the industry to promote a more sustainable approach are only some of the topics touched.
“The concept of sustainability is at the core of IBSA’s strategy, and also concerns the supply chain”, added Marco Falso, Sr. Purchasing Manager of IBSA Group. “The value of our company lies not only in the excellence of our products and our technologies, but also in our ability to build and consolidate our relationships with an entire supply chain that embraces our philosophy and our vision. We cannot consider ourselves truly sustainable if our entire value chain is not. This is an important message, that we also want to convey to all our current and potential partners and collaborators”.